Abstract
Despite their promise as drug targets, access to nitrogen-rich S(VI) compounds has been a significant synthetic challenge. In this issue of Chem, Zhang and Willis explore a new class of S(VI) compounds—sulfondiimidamides—providing robust strategies toward their synthesis, derivation, and promise as new sulfonamide bioisosteres.
Organosulfur compounds have served as powerful tools in various scientific applications ranging from agrochemicals to materials. Since the discovery of sulfonamides (RSO2NR2) in the early 20th century, S(VI)-based “sulfa” drugs have been pivotable in medicinal breakthroughs from antibiotics to anticonvulsants. Nitrogen-based S(VI) compounds represent nearly 25% of all sulfur-based FDA-approved drugs. Of this class of sulfur-based drugs, sulfonamides represent the vast majority. In contrast, more complex nitrogen-based S(VI) compounds that diverge from the sulfonamide manifold, such as sulfamates and sulfamides, represent only around 2% of sulfur-based FDA-approved drugs.1 Together, their shared S=O and S–N bond architecture manifests in drug compounds with similar physicochemical profiles, metabolic and chemical stability, heteroatom-rich composition, and favorable bioactivity profiles.2 The next frontier of S(VI) compounds is the exchange of the oxygen atoms in sulfonamides for nitrogen. Adding more nitrogen groups enables further functionalization of the S(VI) core, opening a new chemical space for bioisosteres of sulfonamides.3 Recent work by Arvidsson and co-workers3 and Stockman, Lückling, and colleagues4 showed promise for this strategy, where the replacement of a S=O bond in sulfonamides with a sulfonimidoyl S=NR bond resulted in sulfonimidamides incorporating new functionalizable N-imidic groups. However, further addition of nitrogen atoms toward more nitrogen-rich derivatives of sulfonamides has been hindered by the dearth of facile synthetic tools for accessing them.5
In this issue of Chem, Zhang and Willis6 have entered a novel chemical space in the synthesis and derivatization of a new class of nitrogenous S(VI) compounds: sulfondiimidamides.5 Their strategy centers on incorporating two different imidoyl groups, resulting in unsymmetrical sulfondiimidamides. This approach expands the number of nitrogen sites available for functionalization. As a result, it enables broader S(VI) structural diversity, unlocking the potential of sulfondiimidamides as valuable hubs for drug design and discovery. En route to sulfondiimidamides, Willis and co-workers’ strategy centers around the synthesis of sulfondiimidoyl fluorides followed by sulfur-fluoride exchange (SuFEx) with amines. Notably, applying S(VI) fluorides in organic synthesis has experienced exponential growth. Pi donation from the fluorine atom to sulfur attenuates the electrophilicity of the sulfur atom and renders the sulfur(VI) fluoride more stable than the chlorinated analogs. As a result, the installation of fluorine in S(VI) organic compounds introduces a functional group that is hydrolytically stable, is resistant to reduction and oxidation chemistry, and reacts selectively at the sulfur atom.7 These properties are helpful for the generation of bench-stable libraries of sulfur(VI) precursors that are readily available for synthetic transformations.
Inspired by their previous work on synthesizing sulfondiimines,8 Zhang and Willis employed N-trimethylsilyl-t-octyl sulfinylamine 1 and Grignard or organolithium reagents to first access in situ sulfinamide 2 and then performed a N-nosyl (Ns) protection to form the unsymmetrical N-Ns N-t-octyl sulfinamidines 3 in good yield. Sulfinamidines 3 in the presence of NaH and electrophilic fluorinating reagent N-fluorobenzenesulfonimide (NFSI) generated a broad set of alkyl, alkenyl, and aryl/heteroaryl sulfondiimidoyl fluorides (Figure 1A).6 There are essential items for consideration in this synthesis. First, sulfinylamines and t-octyl-protected sulfinamidines could be susceptible to SO2 formation via hydrolysis, so the authors advised avoiding water and prolonged storage at room temperature. Similarly, t-octyl protected primary sulfinamidines are sensitive to heat and moisture and are used in their crude form after nosylation. Finally, converting sulfinamides 3 to sulfondiimidoyl fluorides 4 involves allowing the crude material to sit for 1–8 days—depending on the molecule—to allow for isomerization of the N-fluorinated product to the S-fluorinated product. Nevertheless, the authors note that the sulfondiimidoyl fluorides are isolable and stable.
Figure 1.
Synthesis and transformations of sulfondiimidamines
With sulfondiimidoyl fluorides in hand, Zhang and Willis used Lewis acidic calcium bistriflimide—Ca(NTf2)2—to affect SuFEx with a wide range of secondary amines to make sulfondiimidamides.9 Demonstrating the utility of the chemistry in drug development, they also synthesized sulfondiimidamide-based derivatives of amoxapine, clopidogrel, risperidone, and others that have applications ranging from antipsychotics to treating Parkinson’s disease (Figure 1B). SuFEx using Ca(NTf2)2 with primary amines proved challenging because of the suspected catalyst deactivation. As a workaround, imidazole-based sulfondiimidamides (5) were first synthesized with Ca(NTf2)2, sulfondiimidoyl fluoride, and imidazole. Next, the imidazole moiety was converted to a better leaving group via methylation with MeOTf to form a sulfondiimidamidium salt. Subsequent SuFEx with primary amines resulted in sulfondiimidamides in good to excellent yields (Figure 1B). This strategy was also successful in adding azoles and amino heterocycles to their corresponding sulfondiimidamides.
The key feature of this work is the ability to utilize the unsymmetrical nature of the sulfondiimidamides to incorporate structural diversity at the S(VI) core via selective transformations at the nitrogen atoms. The first example demonstrated the derivatization of the amino group (NH2) of sulfondiimidamide 6. Under the appropriate conditions, the addition of acyl chloride or isocyanate readily formed an amide or urea, respectively. Taking advantage of the unsymmetric nature of the differently protected imidic groups of sulfondiimidamide 7, trifluoroacetic acid (TFA) deprotection of the N-t-octyl imidic moiety allowed for the generation of a free NH imidic group. NH-imidic sulfondiimidamide could then undergo cyanation, sulfonylation, acylation, isocyanation, and subsequent deprotection of the N-nosyl imine, yielding functionalized unsymmetric sulfondiimidamides. Observing that imidic N-cyano moieties are found in several bioactive molecules, Zhang and Willis next utilized the free imido group of cyanated sulfondiimidamide 8 toward the addition of SCF3, aryl, carbamate, propargyl, and benzyl groups (Figure 1C). These transformations exhibited the robustness of the sulfondiimidamide core to challenging reaction conditions, including metal catalysis, oxidization, and a strong base.
To exhibit the potential of sulfondiimidamides more directly in drug discovery, the authors next sought to build upon the demonstrated success of N–CN-substituted sulfoximines as COX-2 inhibitors by synthesizing N–CN sulfondiimidamide derivatives of celecoxib.10
Utilizing the chemistries above toward sulfondiimidamides, they synthesized both mono N–CN and bis(N–CN) sulfondiimidamides of celecoxib by using Ca(NTf2)2-mediated SuFEx, sequential deprotections, and cyanations. Calculations on the SwissADME platform demonstrated that, compared with the original compound, both sulfondiimidamide derivatives of celecoxib have promising physiological properties (Figure 1C)
In summary, this work by Zhang and Willis opens long-elusive avenues toward nitrogen-rich bioisoteres of sulfonamides. The three-stage approach—sulfinamide generation, transformation to sulfondimidoyl fluoride, and then SuFEx toward unsymmetrical sulfondiimidamides—introduces a new class of S(VI) compounds that are highly functionalizable and shows promise for drug discovery. Future applications could tap into the chiral nature of the sulfur center, which might have additional potential in catalysis, synthesis, chemical biology, and beyond.
Footnotes
DECLARATION OF INTERESTS
The author declares no competing interests.
References
- 1.Scott KA, and Njardarson JT (2018). Analysis of US FDA-approved drugs containing sulfur atoms. Top. Curr. Chem 376, 5. 10.1007/s41061-018-0184-5. [DOI] [PubMed] [Google Scholar]
- 2.McGrath NA, Brichacek M, and Njardarson JT (2010). A graphical journey of innovative organic architectures that have improved our lives. J. Chem. Educ 87, 1348–1349. 10.1021/ed1003806. [DOI] [Google Scholar]
- 3.Sehgelmeble F, Janson J, Ray C, Rosqvist S, Gustavsson S, Nilsson LI, Minidis A, Holenz J, Rotticci D, Lundkvist J, and Arvidsson PI (2012). Sulfonimidamides as sulfonamides bioisosteres: Rational evaluation through synthetic, in vitro, and in vivo studies with g-secretase inhibitors. ChemMedChem 7, 396–399. 10.1002/cmdc.201200014. [DOI] [PubMed] [Google Scholar]
- 4.Izzo F, Schäfer M, Lienau P, Ganzer U, Stockman R, and Lücking U (2018). Exploration of novel chemical space: Synthesis and in vitro evaluation of N-functionalized tertiary sulfonimidamides. Chem. Eur. J 24, 9295–9304. 10.1002/chem.201801557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Yagupol’skii LM, Bezdudnyi AV, and Yagupol’skii YL (2006). Unusual reactions of N-(trifluoromethylsulfonylimino)di-and-trifluoromethanesulfinimidoyl chlorides. Russ. J. Org. Chem 42, 1275–1279. 10.1134/S1070428006090041. [DOI] [Google Scholar]
- 6.Zhang Z-X, and Willis MC (2022). Sulfondiimidamides as new functional groups for synthetic and medicinal chemistry. Chem 8, 1137–1146. 10.1016/j.chempr.2022.02.013. [DOI] [Google Scholar]
- 7.Dong J, Krasnova L, Finn MG, and Sharpless KB (2014). Sulfur(VI) fluoride exchange (SuFEx): Another good reaction for click chemistry. Angew. Chem. Int. Ed 53, 9430–9448. 10.1002/anie.201309399. [DOI] [PubMed] [Google Scholar]
- 8.Zhang Z-X, Davies TQ, and Willis MC (2019). Modular sulfondiimine synthesis using a stable sulfinylamine reagent. J. Am. Chem. Soc 141, 13022–13027. 10.1021/jacs.9b06831. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Mahapatra S, Woroch CP, Butler TW, Carneiro SN, Kwan SC, Khasnavis SR, Gu J, Dutra JK, Vetelino BC, Bellenger J, et al. (2020). SuFEx activation with Ca(NTf2)2: A unified strategy to access sulfamides, sulfamates, and sulfonamides from S(VI) fluorides. Org. Lett 22, 4389–4394. 10.1021/acs.orglett.0c01397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Park SJ, Baars H, Mersmann S, Buschmann H, Baron JM, Amann PM, Czaja K, Hollert H, Bluhm K, Redelstein R, and Bolm C (2013). N-cyano sulfoximines: COX inhibition, anticancer activity, cellular toxicity, and mutagenicity. ChemMedChem 8, 217–220. 10.1002/cmdc.201200403. [DOI] [PubMed] [Google Scholar]